James Niedel - Profile and Investment Details

Investor Profile

James Niedel is a Venture Capital, Private Equity Firm based in United States with a diverse investment portfolio that includes companies such as iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics, Karyopharm Therapeutics, CRISPR Therapeutics, Kit Check, Advanced Cell Diagnostics, Wave Life Sciences, IRLAB Therapeutics, Arvinas, Versartis, Edge Therapeutics, Alector, UNUM Therapeutics, Aptinyx, AwarepointHarpoon Therapeutics, CardioKinetix, Intarcia Therapeutics, Cogent Biosciences, Relypsa, Neurana Pharmaceuticals, Treato, Rallybio, ReViral, Afferent Pharmaceuticals, Karus Therapeutics, Principia Biopharma, Pearl Therapeutics, ReShape Lifesciences, Catalyst Pharmaceuticals Partners, GluMetrics, Kalidex Pharmaceuticals, Oxford Immunotec, IlluminOss Medical, Aviir, Kyruus, Renovacor, Glympse Bio, CuraSen Therapeutics, Access Closure, BioRelix, DiCE Molecules, Passage Bio, Qlaris Bio, Technology Will Save Us, Neuronetics, AiCure, True North Therapeutics, TigerConnect, Dimension Therapeutics, Presidio Pharmaceuticals, Bellus Health, BrightInsight, Truveris, Iterum Therapeutics, ObsEva, Deciphera Pharmaceuticals, QPID Health, . Over time, James Niedel has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether James Niedel is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Cybersecurity, Messaging, Wellness, Women Founded, Enterprise Software, Rare Diseases, Medical Software, Healthcare Innovation, Life Science, Portfolio Management, Medical Technologies, Artificial Intelligence (AI), Analytics, Venture Fundraising, Software, Manufacturing, Biotechnology, Healthcare IT, Medical Devices, Legal Tech, Innovation, Neuroscience, Clinical Trials, Natural Language Processing, Gene Therapy, Personalized Medicine, Medical Diagnostics, Digital Health, Regulatory Compliance, Nanotechnology, Medical, Information Technology, B2B, Therapeutics, Health Tech, Media and Entertainment, Machine Learning, Pharmaceuticals, Healthcare Technology may find it worthwhile to explore potential connections with James Niedel, as their portfolio suggests a familiarity and interest in this area.

Understanding James Niedel’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.